View in EDS HTML Full Text PDF Full Text

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials.

Saved in:
Bibliographic Details
Title: Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials.
Authors: Hudeček J; 1Department of Research IT, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Voorwerk L; 2Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van Seijen M; 3Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Nederlof I; 2Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., de Maaker M; 3Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van den Berg J; 4Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van de Vijver KK; 5Department of Pathology, Ghent University Hospital, Ghent, Belgium., Sikorska K; 6Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Adams S; 7Department of Medicine, Perlmutter Cancer Center, New York University School of Medicine, New York, NY USA., Demaria S; 8Department of Radiation Oncology, Weill Cornell Medicine, New York, NY USA.; 9Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY USA., Viale G; 10International Breast Cancer Study Group Central Pathology Office, Department of Pathology and Laboratory Medicine, IEO European Institute of Oncology IRCCS, Milan, Italy.; 11University of Milan, Milan, Italy., Nielsen TO; 12Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC Canada., Badve SS; 13Department of Pathology and Laboratory Medicine, Indiana University Simon Cancer Center, Indianapolis, IN USA., Michiels S; 14Service de Biostatistique et d'Epidémiologie, Gustave Roussy, CESP, Université-Paris Sud, Université Paris-Saclay, Villejuif, France.; 15CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, Villejuif, France., Symmans WF; 16Department of Pathology, M.D. Anderson Cancer Center, Houston, TX USA., Sotiriou C; 17Breast Cancer Translational Research Laboratory, Institut Jules Bordet, U-CRC, Université Libre de Bruxelles, Brussels, Belgium., Rimm DL; 18Department of Pathology, Yale School of Medicine, New Haven, CT USA.; 19Department of Medicine, Yale University School of Medicine, New Haven, CT USA., Hewitt SM; 20Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD USA., Denkert C; 21Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany.; 22Institute of Pathology, Philipps-University Marburg, Marburg, Germany., Loibl S; 23German Breast Group, Neu-Isenburg, Germany., Loi S; 24Division of Research and Clinical Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC Australia., Bartlett JMS; 25Ontario Institute for Cancer Research, Toronto, ON Canada.; 26IGMM, Edinburgh, UK.; 27Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK., Pruneri G; 28Department of Pathology and Laboratory Medicine, IRCCS Fondazion - Instituto Nazionale Tumori, Milan, Italy.; 29School of Medicine, University of Milan, Milan, Italy., Dillon DA; 30Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA USA., Cheang MCU; 31Clinical Trials and Statistics Unit, The Institute of Cancer Research, Surrey, UK., Tutt A; 32Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Hall JA; Research and Development, Vivactiv Ltd, Chesham, Buckinghamshire UK., Kos Z; 34Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, ON Canada., Salgado R; 24Division of Research and Clinical Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC Australia.; Department of Pathology, GZA-ZNA Ziekenhuizen, Antwerp, Belgium., Kok M; 2Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; 36Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Horlings HM; 3Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; 4Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Corporate Authors: International Immuno-Oncology Biomarker Working Group
Source: NPJ breast cancer [NPJ Breast Cancer] 2020 May 12; Vol. 6, pp. 15. Date of Electronic Publication: 2020 May 12 (Print Publication: 2020).
Publication Type: Journal Article; Review
Journal Info: Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: eCollection Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 32436923
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Hudeček+J%22">Hudeček J</searchLink>; 1Department of Research IT, The Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Voorwerk+L%22">Voorwerk L</searchLink>; 2Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+Seijen+M%22">van Seijen M</searchLink>; 3Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Nederlof+I%22">Nederlof I</searchLink>; 2Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22de+Maaker+M%22">de Maaker M</searchLink>; 3Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+den+Berg+J%22">van den Berg J</searchLink>; 4Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+de+Vijver+KK%22">van de Vijver KK</searchLink>; 5Department of Pathology, Ghent University Hospital, Ghent, Belgium.<br /><searchLink fieldCode="AU" term="%22Sikorska+K%22">Sikorska K</searchLink>; 6Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Adams+S%22">Adams S</searchLink>; 7Department of Medicine, Perlmutter Cancer Center, New York University School of Medicine, New York, NY USA.<br /><searchLink fieldCode="AU" term="%22Demaria+S%22">Demaria S</searchLink>; 8Department of Radiation Oncology, Weill Cornell Medicine, New York, NY USA.; 9Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY USA.<br /><searchLink fieldCode="AU" term="%22Viale+G%22">Viale G</searchLink>; 10International Breast Cancer Study Group Central Pathology Office, Department of Pathology and Laboratory Medicine, IEO European Institute of Oncology IRCCS, Milan, Italy.; 11University of Milan, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Nielsen+TO%22">Nielsen TO</searchLink>; 12Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC Canada.<br /><searchLink fieldCode="AU" term="%22Badve+SS%22">Badve SS</searchLink>; 13Department of Pathology and Laboratory Medicine, Indiana University Simon Cancer Center, Indianapolis, IN USA.<br /><searchLink fieldCode="AU" term="%22Michiels+S%22">Michiels S</searchLink>; 14Service de Biostatistique et d'Epidémiologie, Gustave Roussy, CESP, Université-Paris Sud, Université Paris-Saclay, Villejuif, France.; 15CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, Villejuif, France.<br /><searchLink fieldCode="AU" term="%22Symmans+WF%22">Symmans WF</searchLink>; 16Department of Pathology, M.D. Anderson Cancer Center, Houston, TX USA.<br /><searchLink fieldCode="AU" term="%22Sotiriou+C%22">Sotiriou C</searchLink>; 17Breast Cancer Translational Research Laboratory, Institut Jules Bordet, U-CRC, Université Libre de Bruxelles, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Rimm+DL%22">Rimm DL</searchLink>; 18Department of Pathology, Yale School of Medicine, New Haven, CT USA.; 19Department of Medicine, Yale University School of Medicine, New Haven, CT USA.<br /><searchLink fieldCode="AU" term="%22Hewitt+SM%22">Hewitt SM</searchLink>; 20Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD USA.<br /><searchLink fieldCode="AU" term="%22Denkert+C%22">Denkert C</searchLink>; 21Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany.; 22Institute of Pathology, Philipps-University Marburg, Marburg, Germany.<br /><searchLink fieldCode="AU" term="%22Loibl+S%22">Loibl S</searchLink>; 23German Breast Group, Neu-Isenburg, Germany.<br /><searchLink fieldCode="AU" term="%22Loi+S%22">Loi S</searchLink>; 24Division of Research and Clinical Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC Australia.<br /><searchLink fieldCode="AU" term="%22Bartlett+JMS%22">Bartlett JMS</searchLink>; 25Ontario Institute for Cancer Research, Toronto, ON Canada.; 26IGMM, Edinburgh, UK.; 27Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK.<br /><searchLink fieldCode="AU" term="%22Pruneri+G%22">Pruneri G</searchLink>; 28Department of Pathology and Laboratory Medicine, IRCCS Fondazion - Instituto Nazionale Tumori, Milan, Italy.; 29School of Medicine, University of Milan, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Dillon+DA%22">Dillon DA</searchLink>; 30Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA USA.<br /><searchLink fieldCode="AU" term="%22Cheang+MCU%22">Cheang MCU</searchLink>; 31Clinical Trials and Statistics Unit, The Institute of Cancer Research, Surrey, UK.<br /><searchLink fieldCode="AU" term="%22Tutt+A%22">Tutt A</searchLink>; 32Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.<br /><searchLink fieldCode="AU" term="%22Hall+JA%22">Hall JA</searchLink>; Research and Development, Vivactiv Ltd, Chesham, Buckinghamshire UK.<br /><searchLink fieldCode="AU" term="%22Kos+Z%22">Kos Z</searchLink>; 34Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, ON Canada.<br /><searchLink fieldCode="AU" term="%22Salgado+R%22">Salgado R</searchLink>; 24Division of Research and Clinical Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC Australia.; Department of Pathology, GZA-ZNA Ziekenhuizen, Antwerp, Belgium.<br /><searchLink fieldCode="AU" term="%22Kok+M%22">Kok M</searchLink>; 2Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; 36Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Horlings+HM%22">Horlings HM</searchLink>; 3Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; 4Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22International+Immuno-Oncology+Biomarker+Working+Group%22">International Immuno-Oncology Biomarker Working Group</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101674891%22">NPJ breast cancer</searchLink> [NPJ Breast Cancer] 2020 May 12; Vol. 6, pp. 15. <i>Date of Electronic Publication: </i>2020 May 12 (<i>Print Publication: </i>2020).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Review
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Breast+Cancer+Research+Foundation%22">Breast Cancer Research Foundation </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101674891 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2374-4677 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223744677%22">23744677 </searchLink><i>NLM ISO Abbreviation: </i>NPJ Breast Cancer <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=32436923
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41523-020-0155-1
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 15
    Titles:
      – TitleFull: Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Hudeček J
      – PersonEntity:
          Name:
            NameFull: Voorwerk L
      – PersonEntity:
          Name:
            NameFull: van Seijen M
      – PersonEntity:
          Name:
            NameFull: Nederlof I
      – PersonEntity:
          Name:
            NameFull: de Maaker M
      – PersonEntity:
          Name:
            NameFull: van den Berg J
      – PersonEntity:
          Name:
            NameFull: van de Vijver KK
      – PersonEntity:
          Name:
            NameFull: Sikorska K
      – PersonEntity:
          Name:
            NameFull: Adams S
      – PersonEntity:
          Name:
            NameFull: Demaria S
      – PersonEntity:
          Name:
            NameFull: Viale G
      – PersonEntity:
          Name:
            NameFull: Nielsen TO
      – PersonEntity:
          Name:
            NameFull: Badve SS
      – PersonEntity:
          Name:
            NameFull: Michiels S
      – PersonEntity:
          Name:
            NameFull: Symmans WF
      – PersonEntity:
          Name:
            NameFull: Sotiriou C
      – PersonEntity:
          Name:
            NameFull: Rimm DL
      – PersonEntity:
          Name:
            NameFull: Hewitt SM
      – PersonEntity:
          Name:
            NameFull: Denkert C
      – PersonEntity:
          Name:
            NameFull: Loibl S
      – PersonEntity:
          Name:
            NameFull: Loi S
      – PersonEntity:
          Name:
            NameFull: Bartlett JMS
      – PersonEntity:
          Name:
            NameFull: Pruneri G
      – PersonEntity:
          Name:
            NameFull: Dillon DA
      – PersonEntity:
          Name:
            NameFull: Cheang MCU
      – PersonEntity:
          Name:
            NameFull: Tutt A
      – PersonEntity:
          Name:
            NameFull: Hall JA
      – PersonEntity:
          Name:
            NameFull: Kos Z
      – PersonEntity:
          Name:
            NameFull: Salgado R
      – PersonEntity:
          Name:
            NameFull: Kok M
      – PersonEntity:
          Name:
            NameFull: Horlings HM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 12
              M: 05
              Text: 2020 May 12
              Type: published
              Y: 2020
          Identifiers:
            – Type: issn-print
              Value: 2374-4677
          Numbering:
            – Type: volume
              Value: 6
          Titles:
            – TitleFull: NPJ breast cancer
              Type: main
ResultId 1